PATENT L Parks
1390-0126P7-25-02
#5/IDS

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

MAISI, Paivi et al.

Appl. No.:

NEW

Group:

Filed:

October 19, 2001

Examiner:

For:

METHODS AND TEST KITS FOR EVALUATING THE

PRESENCE AND SEVERITY OF RESPIRATORY

TRACT INFLAMMATION

INFORMATION DISCLOSURE STATEMENT (SUBMISSION CONCURRENT WITH THE FILING OF A NEW PATENT APPLICATION)

Assistant Commissioner for Patents Washington, DC 20231

October 19, 2001

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

# I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

### II. COPIES

- Submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should be forwarded from the International Search Authority. If copies are needed, please contact the undersigned.

Docket No. 1390-0126P

# III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

# a. DOCUMENTS IN THE ENGLISH LANGUAGE

The attached patents, publications, or other information in the English language do not require a statement of relevancy.

## b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

#### 

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

### d. OTHER

The following additional information is provided for the Examiner's consideration.

Docket No. 1390-0126P

#### FEES

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Respectfully submitted,
BIRCH, STEWART, KOLASCH & BIRCH, LLP

Leonard R. Svensson, #30,330

P.O. Box 747

Other:

LRS/lmt 1390-0126P Falls Church, VA 22040-0747 (703) 205-8000

(703) 203-8000

(Rev. 09/26/01)





Form PTO-1449 ATTY DOCKET NO. APPLICATION NO. 1390-0126P NEW INFORMATION DISCLOSURE CITATION APPLICANT MAISI, Paivi et al. IN AN APPLICATION (Use several sheets if necessary) FILING DATE October 19, 2001 U.S. PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE NAME 5,736,341 1998-04-07 FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY TRANSLATION SUB WO 9410208 A1 1994-05-11 WIPO WO 0020860 A1 2000-04-13 WIPO OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published Suzuki, Ryujiro et al., "MMP in bronchoalveolar lavage fluid in ARDS and its inhibitor", Surg. Trauma Immunol. Responses, 7(4), 98-102 1998 Mautino, G. et al., "Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics" Am J Respir Cell Mol Biol 1997 Nov.; 17(5):583-91 Bosse, M. et al., "Serum matrix metalloproteinase-9: Tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma", Am J Respir Crit Care Med 1999 Feb.; 159(2):596-602 Burnett, D. et al., "Tissue inhibitor of metalloproteinases and collagenase inhibitory activity in lung secretions from patents with chronic obstructive bronchitis: effect of corticosteroid treatment" Thorax 1986 Oct.; 41(10):740-5 EXAMINER DATE CONSIDERED EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/019248

· .			JC13	Sheet <b>Rec'd P</b> (	2 of :	2 19 0	CT 200	
Form PTO-1449			ATTY DOCKET NO. 1390-0126P	ATTY DOCKET NO.		APPLICATION NO. NEW		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)			MAISI, Paivi et al.					
			October 19, 20	GROUP				
	U	.S. PATENT	DOCUMENTS					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING IF APPR	DATE OPRIATE	
							***	
						_		
				<u> </u>		<u> </u>		
							•	
	FOR	EIGN PATEN	T DOCUMENTS	·				
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION		
						YES	МО	
							,	
			-					
							_	
Отигр	DOCUMENTS (Include Name of the author					0-2-		
journal, ser	ial, symposium, catalog, etc.) date, page(s), vol	ume-issue number(s), p	oublisher, city and/or country when	re published.	a of the fter	(BOOK, Ma	gazine,	
	Mautino, G. "Increased expression of correlation with matrix range 1999 Jan.; 79(1):39-47	ession of tis metalloprotei	sue inhibitor of met nase-9 by macrophage	allopro es in as	teinase thma" La	-1 and ab Inve	loss	
	Mautino, G. "Tissue inhibito fluid from asthmatic subject	or of metallo s" Am J Resp	proteinase-1 levels ir Crit Care Med 199	in bron 99 Jul.;	choalved 60(1):3	olar 1a 324-30	avage	
	Hargreave, FE "The investigate examination" Clin Exp Aller	ation of airw gy 1997 May;	ay inflammation in a 27 Suppl. 1:36-40	asthma:	sputum			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

EXAMINER